• 3634 Citations
  • 32 h-Index
1994 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

  • 3634 Citations
  • 32 h-Index
  • 82 Article
  • 2 Letter
2020

Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia

Poh, C., Arora, M., Ghuman, S. & Tuscano, J., Jan 1 2020, (Accepted/In press) In : Acta Haematologica.

Research output: Contribution to journalArticle

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction

Takebe, N., Beumer, J. H., Kummar, S., Kiesel, B. F., Dowlati, A., O'Sullivan Coyne, G., Piekarz, R., Rubinstein, L., Fogli, L. K., Vaishampayan, U., Goel, S., O'Bryant, C. L., El-Rayes, B. F., Chung, V., Lenz, H. J., Kim, R., Belani, C. P., Tuscano, J., Schelman, W., Moore, N. & 2 others, Doroshow, J. H. & Chen, A. P., Jan 1 2019, (Accepted/In press) In : British Journal of Clinical Pharmacology.

Research output: Contribution to journalArticle

Open Access

A phase I study of the combination of rituximab and ipilimumab in patients with relapsed/ refractory B-cell lymphoma

Tuscano, J. M., Maverakis, E., Groshen, S., Tsao-Wei, D., Luxardi, G., Merleev, A. A., Beaven, A., DiPersio, J. F., Popplewell, L., Chen, R., Kirschbaum, M., Schroeder, M. A. & Newman, E. M., Dec 1 2019, In : Clinical Cancer Research. 25, 23, p. 7004-7013 10 p.

Research output: Contribution to journalArticle

1 Scopus citations

A protective role of aryl hydrocarbon receptor repressor in inflammation and tumor growth

Vogel, C. F. A., Ishihara, Y., Campbell, C. E., Kado, S. Y., Nguyen-Chi, A., Sweeney, C. A., Pollet, M., Stemmann, T. H. & Tuscano, J., May 1 2019, In : Cancers. 11, 5, 589.

Research output: Contribution to journalArticle

Open Access
2 Scopus citations
2018

A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation

Barisone, G., O'Donnell, R. T., Ma, Y., Abuhay, M. W., Lundeberg, K., Gowda, S. & Tuscano, J., Jan 1 2018, In : PLoS One. 13, 1, e0190860.

Research output: Contribution to journalArticle

3 Scopus citations

Infectious risks associated with medicinal Cannabis: Potential implications for immunocompromised patients?

Mchardy, I. H., Romanelli, A. M., Harris, L. J., Opp, G., Gaudino, R., Torres, A., Polage, C. R., Tuscano, J. & Thompson, G. R., Jan 1 2018, (Accepted/In press) In : Journal of Infection.

Research output: Contribution to journalArticle

1 Scopus citations
2017

A microbiome assessment of medical marijuana

Thompson, G. R., Tuscano, J., Dennis, M., Singapuri, A., Libertini, S., Gaudino, R., Torres, A., Delisle, J. M. P., Gillece, J. D., Schupp, J. M. & Engelthaler, D. M., Apr 1 2017, In : Clinical Microbiology and Infection. 23, 4, p. 269-270 2 p.

Research output: Contribution to journalLetter

21 Scopus citations

Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma

Witzig, T. E., Luigi Zinzani, P., Habermann, T. M., Tuscano, J., Drach, J., Ramchandren, R., Kalayoglu Besisik, S., Takeshita, K., Casadebaig Bravo, M. L., Zhang, L., Fu, T. & Goy, A., Oct 1 2017, In : American Journal of Hematology. 92, 10, p. E575-E583

Research output: Contribution to journalArticle

6 Scopus citations

Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance

Rosenberg, A., Brunson, A., Paulus, J. K., Tuscano, J., Wun, T., Keegan, T. H. & Jonas, B., Sep 8 2017, In : Blood Cancer Journal. 7, 9, p. e605

Research output: Contribution to journalArticle

11 Scopus citations
2016

A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: A California Cancer Consortium Study

Kirschbaum, M. H., Frankel, P., Synold, T. W., Zain, J., Claxton, D., Tuscano, J., Newman, E. M., Gandara, D. R. & Lara, P. N., 2016, (Accepted/In press) In : British Journal of Haematology.

Research output: Contribution to journalArticle

A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study

Kirschbaum, M. H., Frankel, P., Synold, T. W., Xie, Z., Yen, Y., Popplewell, L., Chen, R., Aljitawi, O., Tuscano, J., Chan, K. K. & Newman, E. M., Oct 2 2016, In : Leukemia and Lymphoma. 57, 10, p. 2307-2314 8 p.

Research output: Contribution to journalArticle

Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia

Yoshida, S., Tuscano, E., Duong, C., Chung, J. H., Li, Y., Beckett, L. A., Tuscano, J. & Satake, N., Oct 3 2016, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-4 4 p.

Research output: Contribution to journalArticle

3 Scopus citations
1 Scopus citations

Novel targeted therapy for precursor B-cell acute lymphoblastic leukemia: Anti-CD22 antibody-MXD3 antisense oligonucleotide conjugate

Satake, N., Duong, C., Yoshida, S., Oestergaard, M., Chen, C., Peralta, R., Guo, S., Seth, P. P., Li, Y., Beckett, L. A., Chung, J. H., Nolta, J., Nitin, N. & Tuscano, J., 2016, In : Molecular Medicine. 22, p. 632-642 11 p.

Research output: Contribution to journalArticle

7 Scopus citations

The HB22.7–vcMMAE antibody–drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity

Abuhay, M., Kato, J., Tuscano, E., Barisone, G., Sidhu, R. S., O'Donnell, R. T. & Tuscano, J., Oct 1 2016, In : Cancer Immunology, Immunotherapy. 65, 10, p. 1169-1175 7 p.

Research output: Contribution to journalArticle

4 Scopus citations
2015

Efficacy of combined histone deacetylase and checkpoint kinase inhibition in a preclinical model of human Burkitt lymphoma

Kong, Y. G., Barisone, G., Sidhu, R. S., O'Donnell, R. T. & Tuscano, J., Aug 24 2015, In : Molecular Medicine. 21, p. 824-832 9 p.

Research output: Contribution to journalArticle

3 Scopus citations

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era

Diefenbach, C. S., Li, H., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Crump, M., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Stewart, D. A., Kahl, B. S., Friedberg, J. W., Blum, K. A., Habermann, T. M., Tuscano, J., Hoppe, R. T., Horning, S. J. & Advani, R. H., Nov 1 2015, In : British Journal of Haematology. 171, 4, p. 530-538 9 p.

Research output: Contribution to journalArticle

22 Scopus citations

Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: A subset analysis of the North American Intergroup E2496 trial

Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Stewart, D. A., Gordon, L. I., Kahl, B. S., Friedberg, J. W., Blum, K. A., Habermann, T. M., Tuscano, J., Hoppe, R. T. & Horning, S. J., Jun 10 2015, In : Journal of Clinical Oncology. 33, 17, p. 1936-1942 7 p.

Research output: Contribution to journalArticle

15 Scopus citations
2014

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: A California Cancer Consortium Study

Kirschbaum, M. H., Foon, K. A., Frankel, P., Ruel, C., Pulone, B., Tuscano, J. & Newman, E. M., Oct 1 2014, In : Leukemia and Lymphoma. 55, 10, p. 2301-2304 4 p.

Research output: Contribution to journalArticle

40 Scopus citations
20 Scopus citations

Diagnosis and classification of autoimmune hemolytic anemia

Bass, G. F., Tuscano, E. T. & Tuscano, J., 2014, In : Autoimmunity Reviews. 13, 4-5, p. 560-564 5 p.

Research output: Contribution to journalArticle

56 Scopus citations

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: Multicentre, single-arm, phase 2 study

Wang, M., Popplewell, L. L., Collins, R. H., Winter, J. N., Goy, A., Kaminski, M. S., Bartlett, N. L., Johnston, P. B., Lister, J., Fanning, S. R., Tuscano, J., Beck, J. T., Kaya, H., Robeva, A., Fan, J., Klimovsky, J., Cheung, W., Cherfi, A. & O'Connor, O. A., 2014, In : British Journal of Haematology. 165, 4, p. 510-518 9 p.

Research output: Contribution to journalArticle

29 Scopus citations

Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7

Kong, Y., Barisone, G., Abuhay, M., O'Donnell, R. T., Buksh, Z., Yousefian, F. & Tuscano, J., Nov 1 2014, In : Leukemia Research. 38, 11, p. 1320-1326 7 p.

Research output: Contribution to journalArticle

3 Scopus citations

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma

Tuscano, J., Dutia, M., Chee, K., Brunson, A., Reed-Pease, C., Abedi, M., Welborn, J. L. & O'Donnell, R. T., 2014, In : British Journal of Haematology. 165, 3, p. 375-381 7 p.

Research output: Contribution to journalArticle

53 Scopus citations

Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia

Satake, N., Duong, C., Chen, C., Barisone, G., Diaz, E. D., Tuscano, J., Rocke, D. M., Nolta, J. & Nitin, N., Nov 1 2014, In : British Journal of Haematology. 167, 4, p. 487-499 13 p.

Research output: Contribution to journalArticle

10 Scopus citations
2013

Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia

Kato, J., Satake, N., O'Donnell, R. T., Abuhay, M., Lewis, C. & Tuscano, J., Jan 2013, In : Leukemia Research. 37, 1, p. 83-88 6 p.

Research output: Contribution to journalArticle

14 Scopus citations

Randomized phase III trial ofabvdversus stanfordvwith or without radiation therapy in locally extensive and advanced-stage hodgkin lymphoma: An intergroup study coordinated by the eastern cooperative oncology group (E2496)

Gordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Gospodarowicz, M., Advani, R., Kahl, B. S., Friedberg, J. W., Blum, K. A., Habermann, T. M., Tuscano, J., Hoppe, R. T. & Horning, S. J., Feb 20 2013, In : Journal of Clinical Oncology. 31, 6, p. 684-691 8 p.

Research output: Contribution to journalArticle

160 Scopus citations

Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation

Vose, J. M., Habermann, T. M., Czuczman, M. S., Zinzani, P. L., Reeder, C. B., Tuscano, J., Lossos, I. S., Li, J., Pietronigro, D. & Witzig, T. E., Sep 2013, In : British Journal of Haematology. 162, 5, p. 639-647 9 p.

Research output: Contribution to journalArticle

26 Scopus citations

Targeting CD22 in B-cell malignancies: Current status and clinical outlook

Sullivan-Chang, L., O'Donnell, R. T. & Tuscano, J., Aug 2013, In : BioDrugs. 27, 4, p. 293-304 12 p.

Research output: Contribution to journalArticle

39 Scopus citations
2012

CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy

Tuscano, J., Kato, J., Pearson, D., Xiong, C., Newell, L., Ma, Y., Gandara, D. R. & O'Donnell, R. T., Nov 1 2012, In : Cancer Research. 72, 21, p. 5556-5565 10 p.

Research output: Contribution to journalArticle

17 Scopus citations

Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma

Kato, J., Li, Y., Xiao, K., Lee, J. S., Luo, J. T., Tuscano, J. M., O'Donnell, R. T. & Lam, K. S., Jun 4 2012, In : Molecular Pharmaceutics. 9, 6, p. 1727-1735 9 p.

Research output: Contribution to journalArticle

45 Scopus citations

Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-hodgkin's lymphoma

Kato, J., O'Donnell, R. T., Abuhay, M. & Tuscano, J., 2012, In : OncoImmunology. 1, 9, p. 1469-1475 7 p.

Research output: Contribution to journalArticle

12 Scopus citations

Moxetumomab pasudotox: Anti-CD22 immunotoxin oncolytic

Kato, J., O'Donnell, R. T. & Tuscano, J., 2012, In : Drugs of the Future. 37, 8, p. 567-570 4 p.

Research output: Contribution to journalArticle

2011

A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia

Kirschbaum, M. H., Synold, T., Stein, A. S., Tuscano, J., Zain, J. M., Popplewell, L., Karanes, C., O'Donnell, M. R., Pulone, B., Rincon, A., Wright, J., Frankel, P., Forman, S. J. & Newman, E. M., Oct 2011, In : Leukemia. 25, 10, p. 1543-1547 5 p.

Research output: Contribution to journalArticle

14 Scopus citations

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: A California Cancer Consortium trial

Somlo, G., Lashkari, A., Bellamy, W., Zimmerman, T. M., Tuscano, J., O'Donnell, M. R., Mohrbacher, A. F., Forman, S. J., Frankel, P., Chen, H. X., Doroshow, J. H. & Gandara, D. R., Aug 2011, In : British Journal of Haematology. 154, 4, p. 533-535 3 p.

Research output: Contribution to journalArticle

33 Scopus citations

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone

Tuscano, J., Ma, Y., Martin, S. M., Kato, J. & O'Donnell, R. T., Jun 2011, In : Cancer Immunology, Immunotherapy. 60, 6, p. 771-780 10 p.

Research output: Contribution to journalArticle

10 Scopus citations

The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner

Martin, S. M., Churchill, E., McKnight, H., Mahaffey, C. M., Ma, Y., O'Donnell, R. T. & Tuscano, J., 2011, In : Journal of Hematology and Oncology. 4, 49.

Research output: Contribution to journalArticle

4 Scopus citations
2010

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)

O'Donnell, R. T., Martin, S. M., Ma, Y., Zamboni, W. C. & Tuscano, J., Jun 2010, In : Investigational New Drugs. 28, 3, p. 260-267 8 p.

Research output: Contribution to journalArticle

18 Scopus citations

Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model

Tuscano, J., Martin, S. M., Ma, Y., Zamboni, W. & O'Donnell, R. T., May 15 2010, In : Clinical Cancer Research. 16, 10, p. 2760-2768 9 p.

Research output: Contribution to journalArticle

37 Scopus citations

Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders

Sands, J. & Tuscano, J., Mar 2010, In : Autoimmunity Reviews. 9, 5

Research output: Contribution to journalArticle

29 Scopus citations
2009

B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-β receptor II dominant negative mice

Moritoki, Y., Lian, Z. X., Lindor, K., Tuscano, J., Tsuneyama, K., Zhang, W., Ueno, Y., Dunn, R., Kehry, M., Coppel, R. L., Mackay, I. R. & Gershwin, M. E., 2009, In : Hepatology. 50, 6, p. 1893-1903 11 p.

Research output: Contribution to journalArticle

74 Scopus citations

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis

Tuscano, J. & Sands, J., 2009, In : Biologics: Targets and Therapy. 3, p. 225-232 8 p.

Research output: Contribution to journalArticle

5 Scopus citations
57 Scopus citations
6 Scopus citations
10 Scopus citations

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

Habermann, T. M., Lossos, I. S., Justice, G., Vose, J. M., Wiernik, P. H., McBride, K., Wride, K., Ervin-Haynes, A., Takeshita, K., Pietronigro, D., Zeldis, J. B. & Tuscano, J., May 2009, In : British Journal of Haematology. 145, 3, p. 344-349 6 p.

Research output: Contribution to journalArticle

206 Scopus citations

Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells

O'Donnell, R. T., Pearson, D., McKnight, H. C., Ma, Y. P. & Tuscano, J., Jul 2009, In : Leukemia Research. 33, 7, p. 964-969 6 p.

Research output: Contribution to journalArticle

4 Scopus citations

Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy

O'Donnell, R. T., Pearson, D., McKnight, H. C., Ma, Y. P. & Tuscano, J., Oct 2009, In : Cancer Immunology, Immunotherapy. 58, 10, p. 1715-1722 8 p.

Research output: Contribution to journalArticle

5 Scopus citations